Results from the Phase 3 VISIONARY trial showed a 97.1% reduction in the risk of a composite kidney outcome event of kidney ...

SIMTRIYO is the first and only norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) approved for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at ...

Ulefnersen demonstrated a statistically significant improvement versus placebo on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the ...

Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The ...

June 17, 2019 – Princeton, NJ - Otsuka America Pharmaceutical, Inc. (Otsuka) has commissioned an innovative and interactive digital art installation, "Light the Way", which is currently on display at ...

TOKYO, JAPAN – November 4, 2017 Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced detailed results from the Phase 3 REPRISE trial of tolvaptan, which is under investigation in the United States ...

Based on the corporate philosophy of Otsuka-people creating new products for better health worldwide, the Otsuka group of companies strives to contribute to the health of people around the world. As a ...

Otsuka is a healthcare company driven by our purpose and defined by our beliefs.

At Otsuka, we’re working to lead an industry-wide shift in the ways caregivers are valued and supported. We are committed to caring for caregivers—standing with them, the way they stand with their ...

This Otsuka America Pharmaceutical, Inc. (“OAPI”) Returned Goods Policy (“Policy”) applies to all pharmaceutical products sold by OAPI (collectively referred to herein as (“Product(s)”). OAPI reserves ...

With over 30 years of experience across various financial and strategic leadership positions in healthcare, Steve is passionate about helping organizations make enterprise-level decisions that drive ...